Research institutes in Bengaluru, Hyderabad, New Delhi and Pune form these four clusters. “The consortium will track the emergence of viral variants correlated to epidemiological and clinical outcomes,” the media statement from Bengaluru based National Centre for Biological Sciences (NCBS), which is a part of the consortium, said.
The CSIR and Laxai Life Sciences Private Limited have initiated phase II clinical trials of anti-helminitic drug ‘Niclosamide’ for the treatment of COVID-19 patients, a statement said on Sunday.